We are live on ! Find out more
BBH icon

VanEck Biotech ETF

83 hedge funds and large institutions have $67.8M invested in VanEck Biotech ETF in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

1% more funds holding

Funds holding: 8283 (+1)

0.58% less ownership

Funds ownership: 16.92%16.34% (-0.58%)

9% less call options, than puts

Call options by funds: $1.27M | Put options by funds: $1.4M

10% less capital invested

Capital invested by funds: $75.4M → $67.8M (-$7.53M)

57% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 30

Holders
83
Holders Change
+1
Holders Change %
+1.22%
% of All Funds
1.9%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
13
Reduced
30
Closed
8
Calls
$1.27M
Puts
$1.4M
Net Calls
-$132K
Net Calls Change
-$1.71M

BBH Hedge Fund Activity: Q2 2018 in Review

83 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2018, worth a combined $67.8M — down 10% from $75.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BBH positions and 8 closed out — a net gain of 1 holder — while 13 added to existing stakes and 30 trimmed.

The largest buyer was Conservest Capital Advisors, opening a new position worth an estimated $1.18M. The largest seller was Susquehanna International Group, cutting an estimated $2.58M.

  • 83 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2018, up from 82 in Q1 2018.
  • Funds reported $67.8M of VanEck Biotech ETF stock for Q2 2018, down 10% quarter-over-quarter.
  • 9 funds opened new VanEck Biotech ETF positions in Q2 2018 and 8 closed out, a net change of +1 holder.
  • The largest VanEck Biotech ETF buyer in Q2 2018 was Conservest Capital Advisors, an estimated $1.18M added.
  • The largest VanEck Biotech ETF seller in Q2 2018 was Susquehanna International Group, an estimated $2.58M sold.

Based on aggregated 13F filings for Q2 2018.